Reckitt Benckiser Completes Acquisition of Adams Respiratory Therapeutics, Inc.
30 Enero 2008 - 6:00AM
PR Newswire (US)
CHESTER, N.J. and SLOUGH, England, Jan. 30 /PRNewswire/ -- Reckitt
Benckiser Group plc (RB.L) ("Reckitt Benckiser") today announced
the successful completion of its acquisition of Adams Respiratory
Therapeutics, Inc. (NASDAQ:ARxT) ("Adams") through a cash tender
offer followed by a short- form merger of its indirect wholly owned
subsidiary, Twickenham Inc., with and into Adams. As a result of
this acquisition, Adams becomes an indirect wholly owned subsidiary
of Reckitt Benckiser. At the effective time of the merger, all
outstanding shares of Adams common stock not validly tendered and
accepted for payment in the tender offer were converted into the
right to receive US$60.00 per share in cash (the same price paid in
the tender offer), without interest and subject to applicable
withholding of taxes. American Stock Transfer & Trust Company,
acting as the paying agent for the merger, will mail to the
remaining former shareholders of Adams materials necessary to
exchange their former Adams shares for such payment. As a result of
the merger, Adams shares will be delisted and cease to trade on the
NASDAQ Global Select Market. Notes for Editors Reckitt Benckiser is
a world leader in household cleaning, health and personal care. The
Company is truly global, with over 60 operating companies and some
43 manufacturing facilities worldwide and has sales in 180
countries. Reckitt Benckiser employs 22,000 people around the
world. Amongst the Company's leading brands in household are Lysol,
the world leader in disinfecting cleaning, Calgonit & Finish
& Electrasol, the world leaders in automatic dishwashing,
Woolite, world leader in fine fabrics, Vanish & Spray'n Wash,
world leaders in fabric treatment, Airwick and Mortein, both No.2
brands in air care and pest control respectively. In Health &
Personal Care (25% of net revenues), leading brand positions
include Veet, the world number one depilatory and Dettol the
world's leading antiseptic, Nurofen, the leading European
analgesic, Strepsils, world number one in medicated sore throat,
Gaviscon the No.1 gastro intestinal remedy in UK and Lemsip the UK
No.1 in cold/flu remedies. Reckitt Benckiser is headquartered in
Slough just outside London, UK and is listed on the London stock
exchange. Reckitt Benckiser had net revenues of 4.92bn pounds,
operating profit of 910m pounds, and net income of 674m pounds in
2006. About Adams Respiratory Therapeutics, Inc. Adams is a
specialty pharmaceutical company focused on the late-stage
development, commercialization and marketing of over-the-counter
and prescription pharmaceuticals for the treatment of respiratory
disorders. DATASOURCE: Reckitt Benckiser CONTACT: Mark Wilson,
Corporate Controller and Acting Head of Investor Relations,
investor queries, or Fiona Fong, Head of Corporate Communications,
press queries, both of Reckitt Benckiser, +44 0 1753 217 800; Susan
Gilchrist of Brunswick, +44 0 207 404 5959, or Cindy Leggett Flynn
of Brunswick New York, +1-212-333-3810; Janet M. Barth, SVP
Investor Relations & Corporate Communications, +1-908-879-2428,
or Faith Pomeroy-Ward, Sr. Manager Investor Relations &
Corporate Communications, +1-908-879-1418, both of Adams
Respiratory Therapeutics Web site: http://www.adamsrt.com/
Copyright